Patent Update Central & Peripheral Nervous Systems: Glycine-site NMDA receptor antagonists: an update

Abstract

Animal models predict that antagonists acting at the glycine-site of the N-methyl-D-aspartate (NMDA) receptor have potential in the treatment of stroke, head injury, epilepsy and schizophrenia, and may offer considerable therapeutic advantage over other classes of NMDA antagonists. Recent developments, particularly in the patent literature, are reviewed for the period since June 1995. The available data on three compounds believed to be in clinical development, namely GV150526A (Glaxo Wellcome), ACEA 1021 (CoCensys/Ciba-Geigy) and ZD9379 (Zeneca), are highlighted. Other compound classes discussed include quinoxaline-2,3-diones and analogues, imidazolopyrazinones, pyridone derivatives, benzazepinediones, 2-carboxyindoles, pyridazinoquinolines and miscellaneous other compounds.